JDRF is the leading global organization funding type 1 diabetes (T1D) research. The ongoing dedication to JDRF's mission to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications ensures that there will be a continuous stream of life-changing therapies moving from development through to the marketplace that lessen the impact of T1D. We want to keep people with T1D healthy and safe today until we reach our ultimate goal of a cure and universal prevention of T1D and turn Type One into Type None. JDRF collaborates with a wide spectrum of partners at every stage of the drug and device delivery pipeline and is the only organization with the scientific resources, regulatory influence, and a strategic plan to deliver a world without T1D. JDRF’s influence and leadership extends beyond funding research. We strategically partner with industry, governments, foundations, academia, and clinicians, because curing T1D is a global coordinated effort with JDRF leading the effort. Currently, JDRF is supporting $568 million in active T1D research projects worldwide. In 2016 alone, JDRF’s T1D research funding totaled more than $106 million. JDRF now has more than 570 research projects taking place throughout the globe. JDRF’s 2016 research funding included $78 million in U.S.-based projects and $28 million in international projects. Since its founding in 1970, JDRF’s cumulative research funding totals over $2 billion. JDRF is currently funding more than 50 clinical trials of potential T1D therapies. JDRF has worked with industry experts and established strategic roadmaps in Artificial Pancreas Systems, encapsulation of insulin producing cells, beta cell regeneration, antigen specific immunotherapy, prevention of T1D, prevention or treatment of diabetic complications of the kidney and eye, and other select areas. JDRF will be providing input and expertise to WPs 1, 5, 6, 7 and 8. More specifically, JDRF will be part of the Hypo-RESOLVE steering committee and thus contribute to the strategic governance of the project. JDRF will also be co-leading the Patient Advisory Committee (PAC), which ensures the project’s impact on patients by involving them in all aspects of the project, and advise every work package. The PAC will be involved in the design of the clinical trial, the development of the PRO, as well as communication with patient networks and the general public. Moreover, JDRF will provide regulatory expertise to facilitate the contact with the regulatory authorities both in Europe and in the US. JDRF is also providing an IMI-matched contribution of EUR 1 520 000 to Hypo-RESOLVE.